Generate Biomedicines, Inc 10-Q for FY2026 Q3
Generate Biomedicines, Inc. (GENB)
10-Q
2026-11-12
For: 2026-09-30
View Original
Added on
November 12, 2026
About this 10-Q
Generate Biomedicines, Inc filed this 10-Q on November 12, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).
Generate Biomedicines reported a $216.6 million net loss and $204.4 million in research and development expenses for the nine months ended September 30, 2026; cash, cash equivalents and marketable securities totaled $404.2 million as of September 30, 2026. AI summary
Headline figures
Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $4.22M
- down 56.2% from $9.63M a year earlier
- Net loss
- $87.66M
- compared with a net loss of $53.62M a year earlier
- Diluted EPS
- -$0.68
- compared with -$1.97 a year earlier